Related Experiment Video
Updated: May 13, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma
Young-Won Lee1, Sae-Byul Lee2, Il Yong Chung2
1Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Background:
This study aims to compare the efficacy of 5- versus 10-year endocrine therapy in pure mucinous breast carcinoma (PMBC), focusing on late recurrence and related factors for personalized treatment.
Methods:
Patients with PMBC who underwent surgery from 1996 to 2014 at Asan Medical Center were included. Recurrence was categorized as early (<5 years) or late (≥5 years). The primary endpoint was disease-free survival in the 5- and 10- year endocrine groups. Subgroup analysis was performed focused on clinically high-risk patients (tumor ≥2 cm, nodal metastasis, or high histologic grade).
Results:
A total of 489 patients with PMBC were identified. During a follow-up time of 126 months, 35 (7.2 %) patients had an early recurrence, 25 (5.1 %) patients had a late recurrence, and 394 (87.7 %) patients had no recurrence. High histologic grade was the only factor significantly correlated to late recurrence (hazard ratio 6.92, 95 % confidence interval 1.53-31.3). Among the 5-year disease-free survivors (N = 416), 340 (81.7 %) and 76 (18.3 %) patients underwent 5-year and 10-year endocrine therapy, respectively. Endocrine therapy duration did not impact the 10-year disease-free survival rate (5-year [95.4 %] vs. 10-year [97.3 %] endocrine therapy, log-rank test p = 0.504). Subgroup analysis with clinically high-risk patients revealed no survival difference based on the endocrine therapy duration, too.
Conclusion:
Extended endocrine therapy did not significantly reduce late recurrence in PMBC, even in high-risk groups, underscoring the importance of personalized strategies for sustained outcomes.
